Phase I Clinical Trial of GEN2-Recombinant COVID-19 Vaccine (CHO Cells) in Healthy People Aged 18 and Above

Inclusion Criteria: * Age range: healthy people aged 18 and above, who can provide legal identification; * No history of t SARS-CoV-2 vaccination; * Able to provide a negative nucleic acid test certificate for the new coronavirus within 48 hours; * Have the ability to understand (if illiterate, a fair witness is required to accompany the informed consent) research procedures, have informed consent, voluntarily sign the informed consent form, and be able to comply with the requirements of the clinical research protocol； * Inquire about medical history and physical examination, and the investigator judges that the health status is good; * Females of childbearing age (menarche to menopause) were not pregnant (negative urine pregnancy test) at enrollment, were not breastfeeding, and had no reproductive plans within the first 6 months after enrollment and took effective contraceptive measures; 2 weeks prior to enrollment have taken effective contraceptive measures; * Able and willing to complete the entire prescribed study plan throughout the study follow-up period. Exclusion Criteria: First-dose exclusion criteria： * Confirmed cases, suspected cases, asymptomatic infections, or close contacts of the above-mentioned groups of SARS-CoV-2 infection (check "China Disease Prevention and Control Information System"); * Axillary body temperature ≥37.3℃ before vaccination; * Positive test for novel coronavirus antibody (IgG+IgM); * Have a history of SARS virus infection (self-report,…